Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6662692 | 0.98 | HPGD (0.47) | KMT2AEPHX1HPGDTDP1NPC1 | |
| SCHEMBL3846912 | 0.98 | HPGD (0.47) | KMT2AEPHX1HPGDTDP1NPC1 | |
| SCHEMBL14751461 | 0.95 | — | — | |
| SCHEMBL8618756 | 0.90 | — | — | |
| SCHEMBL19867672 | 0.87 | KMT2A (0.38) | KMT2AEPHX1HPGDTDP1NPC1 | |
| SCHEMBL8106988 | 0.87 | HPGD (0.42) | KMT2AEPHX1HPGDTDP1NPC1 | |
| Thiophene SCHEMBL27503885 | 0.84 | EPHX2 (0.36) | KMT2AEPHX1HPGDTDP1NPC1 | |
| SCHEMBL3116167 | 0.84 | EPHX1 (0.50) | KMT2AEPHX1HPGDNPC1EPHX2 | |
| Thiophene SCHEMBL27537280 | 0.83 | EPHX2 (0.38) | KMT2AEPHX1HPGDTDP1NPC1 | |
| SCHEMBL7945281 | 0.81 | EPHX1 (0.54) | KMT2AEPHX1HPGDNPC1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230338588-A1 | Granzyme B Directed Imaging and Therapy | THE GENERAL HOSPITAL CORPORATION | 2023-10-26 | — | — | US | disclosed |
| US-20210299126-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | BRISTOL-MYERS SQUIBB COMPANY | 2021-09-30 | — | — | US | disclosed |
| US-20190146340-A1 | RADIATION-SENSITIVE RESIN COMPOSITION AND RESIST PATTERN-FORMING METHOD | JSR CORPORATION (JP) | 2019-05-16 | — | — | US | disclosed |
| US-9777280-B2 | Compositions and methods for 3-hydroxypropionic acid production | CARGILL, INCORPORATED (US) | 2017-10-03 | — | — | US | disclosed |
| US-9780121-B2 | Touch sensor, touch panel, and manufacturing method of touch panel | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2017-10-03 | — | — | US | disclosed |
| WO-2017140336-A1 | FRAGRANT MIXTURES CONTAINING ESTERS AND KETONES | SYMRISE AG (DE) | 2017-08-24 | — | — | WO | disclosed |
| EP-2693882-B1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK SHARP & DOHME (US) | 2017-06-28 | — | — | EP | disclosed |
| EP-2209790-B1 | EQUILIBRATIVE NUCLEOSIDE TRANSPORTER ENT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-02-17 | — | — | EP | disclosed |
| US-20150261333-A1 | Touch Panel | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2015-09-17 | — | — | US | disclosed |
| US-20150255518-A1 | Touch Sensor, Touch Panel, and Manufacturing Method of Touch Panel | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2015-09-10 | — | — | US | disclosed |
| US-7645771-B2 | CCR5 antagonists as therapeutic agents | SMITHKLINE BEECHAM CORP. (US) | 2010-01-12 | — | — | US | disclosed |
| US-20090149349-A1 | RECOMBINANT ADENOVIRUSES PREPARATION AND ADENOVIRUS BANKS | AVENTIS PHARMA S.A. (FR) | 2009-06-11 | — | — | US | disclosed |
| US-20090123423-A1 | HYDROXYAMIC ANALOGS AS HEPATITIS C VIRUS SERINE PROTEASE INHIBITOR | ENANTA PHARMACEUTICALS, INC. | 2009-05-14 | — | — | US | disclosed |
| US-20080292587-A1 | OXIMYL DIPEPTIDE HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-11-27 | — | — | US | disclosed |
| US-20080274082-A1 | OXIMYL HYDROXYAMIC ANALOGS AS HEPATITIS C VIRUS PROTEASE INHIBITOR | ENANTA PHARMACEUTICALS, INC. | 2008-11-06 | — | — | US | disclosed |
| US-20080267918-A1 | QUINOXALINYL DIPEPTIDE HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-10-30 | — | — | US | disclosed |
| US-20080032936-A1 | Quinoxalinyl tripeptide hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2008-02-07 | — | — | US | disclosed |
| EP-0207345-B1 | 4,7-Dihydrothieno[2,3-b]pyridine derivatives, process thereof, and agents for cardiovascular diseases | SHIONOGI & CO., LTD. (JP) | 1992-01-22 | — | — | EP | disclosed |
| US-4703051-A | CALCIUM CHANNEL BLOCKERS; HYPOTENSIVES, VASODILATORS | SHIONOGI & CO., LTD. (JP) | 1987-10-27 | — | — | US | disclosed |
| EP-0207345-A2 | 4,7-Dihydrothieno[2,3-b]pyridine derivatives, process thereof, and agents for cardiovascular diseases | SHIONOGI & CO., LTD. (JP) | 1987-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080274082-A1 | OXIMYL HYDROXYAMIC ANALOGS AS HEPATITIS C VIRUS PROTEASE INHIBITOR | HPN, HCCS, SPINT2 | KMT2A 1288/4885EPHX1 180/4885HPGD 174/4885 |
| US-20210299126-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | IDO1, IDO2, INMT | KMT2A 556/4885EPHX1 1127/4885HPGD 103/4885 |
| US-20080292587-A1 | OXIMYL DIPEPTIDE HEPATITIS C PROTEASE INHIBITORS | DPP4, PREP, PEPD | KMT2A 2390/4885EPHX1 688/4885HPGD 853/4885 |
| US-20230338588-A1 | Granzyme B Directed Imaging and Therapy | GZMB, CTSB, PRF1 | KMT2A 4798/4885EPHX1 4155/4885HPGD 2610/4885 |
| US-20080267918-A1 | QUINOXALINYL DIPEPTIDE HEPATITIS C VIRUS INHIBITORS | DPP4, CTSC, PEPD | KMT2A 2412/4885EPHX1 836/4885HPGD 470/4885 |
| US-20090123423-A1 | HYDROXYAMIC ANALOGS AS HEPATITIS C VIRUS SERINE PROTEASE INHIBITOR | HPN, PRSS1, SERPINB1 | KMT2A 2252/4885EPHX1 412/4885HPGD 237/4885 |
| US-20080032936-A1 | Quinoxalinyl tripeptide hepatitis C virus inhibitors | VIP, CTSC, PREP | KMT2A 2491/4885EPHX1 793/4885HPGD 455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.